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A B S T R A C T
Brevibacterium has been reported as a rare cause of
implanted-device infection. In two cases of recur-
rent Brevibacterium casei bacteraemia associated
with infection of surgically implanted intravascu-
lar devices, relapse occurred 2 and 5 months,
respectively, after completion of therapy with
vancomycin via the infected catheter. A second
intravenous antibiotic therapy course by the
antibiotic-lock technique led to bacteriological
cure in one patient. Molecular typing results
demonstrated that the recurrent bacteraemia
was caused by the same strain. Implanted-device
removal may be necessary, in addition to appro-
priate antibiotics, for successful management of
such infections.
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Brevibacterium spp. are non-motile, non-spore
forming, catalase-positive, aerobic Gram-positive
bacilli. They are part of the normal flora of the
skin and adjacent structures, but have been
reported only rarely as causes of human infection,
including endocarditis [1], continuous ambula-
tory peritoneal dialysis peritonitis [2] and bacter-
aemia in compromised hosts with long-term
intravenous devices [3–8]. Other habitats include
raw milk, cheese and animal sources. The genus
Brevibacterium contains at least eight species
(B. linens, B. casei, B. epidermidis, B. iodinum,
B. mcbrellneri, B. otitidis, B. avium and B. paucivo-
rans [9]). Identification to the genus level is
achieved easily with commercial identification
panels, but species identification requires addi-
tional biochemical tests, fatty acid analysis or
genotyping.
Management of catheter-related bloodstream
infection varies according to the type of catheter
involved and the causative pathogen. Removal of
the infected catheter in case of complicated
bacteraemia is consensual [10]. However, for
tunnelled or implanted catheter-related infection,
other factors, including the type of pathogen, local
signs of infection, and the severity of infection are
involved in the decision whether or not to remove
the catheter. Conservative intravenous antibiotic
therapy associated with an antibiotic-lock is
recommended only for uncomplicated bacterae-
mia caused by organisms of low virulence [6].
Table 1 summarises the clinical features of two
unusual cases of recurrent bacteraemia caused by
B. casei that were associated with infected long-
term intravascular access. The first patient was a
43-year-old woman, who suffered from Crohn’s
disease and developed pelvic entero-cutaneous
fistulisations. This required total colectomy with
discharge jejunostomy, which was complicated by
chronic entero-cutaneous fistulae. Since this time,
she received total parenteral nutrition through a
totally implantable intravenous port (Port-
A-Cath). Five years later, she presented with
recurrent pyrexia. The second patient was a
31-year-old man with an implanted Hickman
catheter who became febrile (38.5 C) during
haemodialysis. He had no specific symptoms
and physical examination was normal, with no
sign of catheter infection and no noticeable
inflammatory syndrome. In both cases, blood
culture yielded B. casei, and intravenous therapy
with vancomycin was initiated. Both patients
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improved initially, but were readmitted after
5 months and 2 months, respectively. In both
cases B. casei was again isolated from blood
cultures (Table 1).
The isolates were recovered from Bactec Plus
Aerobic blood culture vials processed in the
automated Bactec 9240 system (Becton Dickinson,
Sparks, MD, USA). Quantitative blood culture
obtained through the catheter was completed
with the Isolator system (Oxoid, Basingstoke,
UK). Identification was performed with the API
Coryne gallery (bioMe´rieux, Marcy l’Etoile,
France), together with tests for production of
a-glucosidase, and oxidation of D-arabinose and
inositol, followed by 16S rRNA gene sequencing.
The isolates were typed by amplified fragment
length polymorphism (AFLPTM) analysis of
genomic DNA as described previously [11]. Anti-
microbial susceptibility testing was performed by
disk diffusion with Neo-Sensitabs (Rosco Diag-
nostics, Taastrup, Denmark) on Mueller Hinton
sheep-blood (Becton Dickinson) agar, and was
interpreted according to the National Committee
for Clinical Laboratory Standards breakpoints for
staphylococci, as recommended in the manufac-
turer’s instructions. Culture of the catheter tip
was performed using Maki’s semi-quantitative
culture method [12].
Gram’s stain on positive blood culture vials
revealed small, regularly shaped, Gram-positive
bacilli. Following sub-culture on blood agar,
smooth, greyish, small colonies appeared after
incubation for 24 h, with a marked cheese-like
smell. The four strains were identified as Brevi-
bacterium spp. by the API Coryne gallery. The
results of complementary tests for a-glucosidase
(positive), D-arabinose (positive) and inositol
(positive) identified the species as B. casei
[13,14]. This identification was corroborated by
16S rRNA gene sequencing (results not shown).
All strains had the same antimicrobial suscepti-
bility profile (Table 1). AFLP typing showed sets
of indistinguishable DNA patterns, demonstra-
ting that the reccurrence of bacteraemia was
caused by a relapsing infection with a single
strain in each of the two patients (Fig. 1).
In both cases, B. casei bacteraemia was caused
by catheter infection, as confirmed by the high
bacterial counts found in per-catheter quantitative
blood cultures.
Both patients presented with a second episode
of bacteraemia, caused by the same strain, several
Table 1. Summary of case reports
Patient 1 (female aged 43 years) Patient 2 (male aged 31 years)
Onset
Readmission
(5 months later) Onset
Readmission
(2 months later)
Clinical findings Fever Confusion, weight loss Fever Fever, chills, cellulitis around
catheter insertion
Inflammatory laboratory tests
CRP 5.8 19 < 0.5 0.9
WBC 3300 < 200 4700 7000
Positive blood cultures 3 Peripheral blood sets 2 Peripheral blood sets 2 Peripheral blood sets 4 Peripheral blood sets
1 Q (> 100 CFU ⁄mL) 1 Q (> 1000 CFU ⁄mL) 1 Q (500 CFU ⁄mL) 1 Q (50 000 CFU ⁄mL)
Strain identification B. casei B. casei B. casei B. casei
Treatment Vancomycin
1 g ⁄day IV (15 days)
Catheter removal plus:
amoxycillin–clavulanate
2 g · 3 ⁄day IV (3 days),
meropenem
1 g · 3 ⁄day IV (3 days),
amikacin 1 g ⁄day IV (3 days)
Vancomycin
1 g ⁄ 72 h IV (15 days)
through the catheter,
after haemodialysis
Vancomycin
1 g ⁄day IV (15 days) and
antibiotic-lock with vancomycin
3 times ⁄week (15 days)
Susceptibility testing Vancomycin, S;
erythromycin, S;
doxycycline, S;
minocycline, S;
gentamicin, S;
amikacin, S;
ciprofloxacin, S;
fusidic acid, I;
penicillin, R;
oxacillin, R;
cotrimoxazole, R;
mupirocin, R
Culture of the tip Not done Done (negative)
Outcome Died Recovered
CRP, C-reactive protein (mg ⁄dL); WBC, total white blood cell count (cells ⁄mm3); Q, quantitative; CFU, colony forming unit; IV, intravenous; S, susceptible; I, intermediate; R,
resistant.
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months after a 15-day course of intravenous
vancomycin therapy, which resulted initially in
the resolution of symptoms and negative blood
cultures. In the first case, bacteraemia was com-
plicated by septic shock and the catheter was
removed. Conversely, the second patient presen-
ted with uncomplicated bacteraemia. As the
implanted catheter was needed for venous access
during haemodialysis, its removal was post-
poned, and the antibiotic-lock technique [10]
was used in conjunction with the intravenous
route. The patient did not present with any
further relapse of bacteraemia. Moreover, when
an arteriovenous fistula came into use subse-
quently , the catheter was removed and cultures
were negative.
For complicated infection, catheter removal is
recommended [7]. However, there is no consensus
about the management of uncomplicated bacter-
aemia induced by the infection of a surgically
implanted intravascular device. Antibiotic-lock
has been proposed for cases of catheter-related
bacteraemia caused by Staphylococcus aureus, co-
agulase-negative staphylococci and Gram-negat-
ive bacilli [10], although evidence for the efficacy
of this approach remains limited. The cases des-
cribed above illustrate that intravenous vancomy-
cin may not be sufficient to eradicate central
catheter colonisation with B. casei, which may
persist even when blood cultures become negat-
ive. Recurrence of bacteraemia caused by the same
strain was demonstrated up to 5 months following
initial adequate therapy. Based on this experience,
it is suggested that implanted-device removal
should be the preferred treatment for associated
B. casei bloodstream infection. However, com-
bined intravenous and lock therapy with vanco-
mycin via the catheter may be attempted in order
to keep a surgically implanted catheter in situ,
which is sometimes of vital importance for the
continued treatment of the patient.
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Fig. 1. Electrophoresis gel of AFLP patterns for the
Brevibacterium. casei isolates: (a) and (b) correspond to the
consecutive isolates from patient 1; (c) was first isolated
from patient 2; (d) and (e) are colony morphology variants
of the second isolate from patient 2. Size markers are Gene
RulerTM, 100 bp DNA Ladder Plus (MBI, Fermentas,
Germany).
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